Premium
Prolonged 14‐day continuous infusion of high‐dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma
Author(s) -
Meazza Cristina,
Casanova Michela,
Luksch Roberto,
Podda Marta,
Favini Francesca,
Cefalo Graziella,
Massimino Maura,
Ferrari Andrea
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22596
Subject(s) - ifosfamide , medicine , mesna , sarcoma , refractory (planetary science) , pediatric cancer , continuous infusion , blood cancer , surgery , urology , chemotherapy , anesthesia , cancer , etoposide , pathology , physics , astrobiology
Background Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate. Prolonged continuous infusion seems an attractive administration modality. Methods Ifosfamide 14 g/m 2 (with mesna 14 g/m 2 ) was administered through an ambulatory portable pump over 14 days as a continuous infusion, starting every 3 weeks, in 14 patients with relapsing sarcomas. No growth factors were given. Results Acute grade 3 hematological toxicity was observed in only 13/66 cycles and red cell transfusions were given in two patients. Hematuria and dysuria occurred in three cases. The response rate was: five partial responses, five stable disease. The median time to progression was 3 months (range: 2–19 months). The best response rate was seen for synovial sarcoma and Ewing sarcoma. Conclusion Prolonged 14‐day continuous infusion of high‐dose ifosfamide is well tolerated. Potentially interesting preliminary responses in pediatric patients already treated with ifosfamide are reported. Pediatr Blood Cancer. 2010;55:617–620. © 2010 Wiley‐Liss, Inc.